Company intelligence / Profile preview
Aegros
Macquarie Park, New South Wales, Australiaaegros.com.au ↗
- Ownership
- Private
- Employees
- ~105
- Development stage
- Commercial
01
Overview
Aegros has developed a TGA GMP-approved plasma fractionation plant in Sydney, producing a hyperimmune immunoglobulin against COVID‑19 from convalescent plasma. The company is finalizing registration of this product on the Australian Register of Therapeutic Goods and completing clinical trials in partnership with a major Sydney hospital.
- Therapeutic areas
- Infectious Diseases
- Modalities
- BiologicPlasma-derived medicinal productsHyperimmune immunoglobulin therapyProtein (immunoglobulins)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Major Sydney hospital for clinical trials of the COVID hyperimmune program
Beyond the preview
Go deeper on Aegros.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aegros.